The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Encorafenib plus binimetinib in patients with locally advanced, unresectable, or metastatic BRAFV600-mutant melanoma: Updated data from the multicenter, multinational, prospective, non-interventional longitudinal study BERINGMELANOMA.
 
Erika Richtig
Honoraria - Amgen; Bayer; Bristol-Myers Squibb; Merck; Merck Sharp Dohme; Novartis; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Merck; Merck Sharp & Dohme; Novartis; Pierre Fabre
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Merck; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); CureVac (Inst); Incyte (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pierre Fabre (Inst); Regeneron (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; Sanofi
 
Carmen Loquai
Consulting or Advisory Role - Almirall Hermal GmbH (Inst); Biontech (Inst); Bristol-Myers Squibb (Inst); Kyowa Kirin International (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi (Inst); Sun Pharma (Inst)
Travel, Accommodations, Expenses - Almirall Hermal GmbH (Inst); Biontech (Inst); Bristol-Myers Squibb (Inst); Kyowa Kirin International (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi (Inst); Sun Pharma (Inst)
 
Andrea Forschner
Honoraria - Bristol-Myers Squibb; CeGaT; MSD Oncology; MSD Oncology; Novartis; Roche Pharma AG
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; Roche Pharma AG
Research Funding - Stiftung Immunonkologie/Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pierre Fabre; Roche
 
Ralf Gutzmer
Honoraria - Almirall Hermal GmbH; Amgen; Bristol-Myers Squibb; Immunocore; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron; Sun Pharma
Consulting or Advisory Role - 4SC; Almirall Hermal GmbH; Amgen; Bristol-Myers Squibb; Immunocore; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi; Sun Pharma
Research Funding - Amgen (Inst); Johnson & Johnson (Inst); Merck Serono (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Sun Pharma (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Pierre Fabre; Roche; Sun Pharma
 
Jessica Cecile Hassel
Honoraria - Almirall Hermal GmbH; Amgen; Bristol Myers Squibb Foundation; GlaxoSmithKline; MSD; Novartis; Pierre Fabre; Roche Pharma AG; Sanofi; Sun Pharma
Consulting or Advisory Role - MSD; Sanofi Aventis GmbH; Sun Pharma
Research Funding - 4SC (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Idera (Inst); Immunocore (Inst); Iovance Biotherapeutics (Inst); Nektar (Inst); Novartis (Inst); Philogen (Inst); Pierre Fabre (Inst); Regeneron (Inst); Sanofi (Inst); Sun Pharma (Inst)
Travel, Accommodations, Expenses - 4SC
 
Jochen Utikal
Stock and Other Ownership Interests - BioNTech; GlaxoSmithKline; Merck; Moderna Therapeutics; MorphoSys; Pfizer; Sanofi
Honoraria - Bristol-Myers Squibb; Immunocore; MSD; Novartis; Pierre Fabre; Sanofi
Consulting or Advisory Role - Bristol-Myers Squibb; Immunocore; MSD; Novartis; Pierre Fabre; Sanofi
Research Funding - Apogenix (Inst); Merck (Inst); Noxxon Pharma (Inst)
Travel, Accommodations, Expenses - Pierre Fabre; Sanofi
 
Sebastian Haferkamp
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre
 
Friedegund Elke Meier
Honoraria - Amgen; Bristol-Myers Squibb; Merck; MSD; Novartis; Roche; Sanofi
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Research Funding - Novartis; Roche
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck; MSD; Novartis; Pierre Fabre; Roche; Sanofi
 
Dirk Debus
Honoraria - Bristol-Myers Squibb; Kyowa Kirin; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis; Pierre Fabre; Roche; Sanofi
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; MSD; Mylan; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
 
Reinhard Dummer
Honoraria - Alligator Bioscience; Amgen; Bristol-Myers Squibb; Catalym; MaxiVax ; MSD; Novartis; Pfizer; Pierre Fabre; Regeneron; Roche; Sanofi; Second Genome; Sun Pharma; T3 Pharmaceuticals; Takeda; touchIME
Consulting or Advisory Role - Alligator Bioscience; Amgen; Bristol-Myers Squibb; Catalym; MaxiVax ; MSD; Novartis; Pfizer; Pierre Fabre; Regeneron; Roche; Sanofi; Second Genome; Sun Pharma; T3 Pharmaceuticals; Takeda; touchIME
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
 
Roger Anton Fredy Von Moos
Honoraria - Amgen; Daiichi Sankyo; Vifor Pharma
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; Lilly; Merck Serono; MSD; PharmaMar; Roche
 
Jan Thompson
Employment - Alcedis; IKF Klinische Krebsforschung
 
Laura Gengenbacher
Employment - Pierre Fabre
Stock and Other Ownership Interests - Pierre Fabre
 
Olivier Michielin
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche
Research Funding - Bristol-Myers Squibb; MSD; NeraCare GmbH
Expert Testimony - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD
 
Christoph Hoeller
Honoraria - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche; Sanofi
Consulting or Advisory Role - Almirall; Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Research Funding - Amgen (Inst)
 
Dirk Schadendorf
Honoraria - 4SC; Amgen; Array BioPharma; Bristol-Myers Squibb; Daiichi Sankyo Japan; Immunocore; InflarxGmbH; LabCorp; Merck Serono; Merck Sharp & Dohme; Nektar; NeraCare GmbH; Novartis; Pfizer; Philogen; Pierre Fabre; Regeneron; Replimune; Roche/Genentech; Sandoz; Sanofi/Regeneron; Sun Pharma; Ultimovacs
Consulting or Advisory Role - 4SC; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; NEKTAR; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
Speakers' Bureau - Bristol-Myers Squibb; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi/Regeneron
Research Funding - Amgen (Inst); Array BioPharma/Pfizer (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron